title: MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study.
abstract: OBJECTIVE
  using a protocol similar to that of the MOVE 1 study in Germany, the multicenter, observational MOVE 1 EU study examined the burden of multiple sclerosis (MS)-related spasticity in other EU countries (Belgium, Finland, France, Ireland, Norway, Poland and Portugal).
  
  
  METHODS
  A 12-month retrospective chart documentation was combined with questionnaires for physicians and patients at the time of enrollment. A total of 281 patients from neurology departments and MS units formed the per protocol population.
  
  
  RESULTS
  in most patients, MS spasticity frequently restricted daily activities and caused some/moderate problems in EQ-5D subdomains of mobility, usual activities and pain/discomfort. Overall, 48% of physicians and 34% of patients were at least partly dissatisfied with the effectiveness of available pharmacotherapy options for MS spasticity.
  
  
  CONCLUSIONS
  Results of the MOVE 1 Germany and MOVE 1 EU studies are aligned and highlight the need to optimize the therapeutic management of patients with MS spasticity across Europe so as to improve their overall well-being and quality of life.
authors.forename: Patrick
authors.initials: P
authors.lastname: Vermersch
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D017281:Cost of Illness; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D009128:Muscle Spasticity / Q000209:etiology / Q000523:psychology* / Q000628:therapy*; D017060:Patient Satisfaction; D011788:Quality of Life
keywords: EU; activities of daily living; burden of disease; multiple sclerosis; pharmacotherapy; quality of life; spasticity; symptoms; treatment satisfaction